Evidence map›Paper›PMID 28566687›Full record

ArticleScientific reports2017

Iterative Sequencing and Variant Screening (ISVS) as a novel pathogenic mutations search strategy - application for TMPRSS3 mutations screen.

Urszula Lechowicz, Tomasz Gambin, Agnieszka Pollak, Anna Podgorska, Piotr Stawinski, Andre Franke, Britt-Sabina Petersen, Malgorzata Firczuk, Monika Oldak, Henryk Skarzynski and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Novel splice-site variants inFrontiers in genetics · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Urszula LechowiczDepartment of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland.
Tomasz GambinInstitute of Computer Science, Warsaw University of Technology, Warsaw, Poland.
Agnieszka PollakDepartment of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland.
Anna PodgorskaDepartment of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland.
Piotr StawinskiDepartment of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland.
Andre FrankeInstitute of Clinical Molecular Biology, Kiel University, Kiel, Germany.ORCID 0000-0003-1530-5811
Britt-Sabina PetersenInstitute of Clinical Molecular Biology, Kiel University, Kiel, Germany.ORCID 0000-0001-9022-9017
Malgorzata FirczukDepartment of Immunology, Center of Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
Monika OldakDepartment of Genetics, Institute of Physiology and Pathology of Hearing, Warsaw, Poland.
Henryk SkarzynskiOto-Rhino-Laryngology Surgery Clinic, Institute of Physiology and Pathology of Hearing, Warsaw, Poland.
Rafal PloskiDepartment of Medical Genetics, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland. rploski@wp.pl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal recessive diseases (ARD) are typically caused by a limited number of mutations whose identification is challenged by their low prevalence. Our purpose was to develop a novel approach allowing an efficient search for mutations causing ARD and evaluation of their pathogenicity without a control group. We developed Iterative Sequencing and Variant Screening (ISVS) approach based on iterative cycles of gene sequencing and mutation screening, and ISVS Simulator software ( http://zsibio.ii.pw.edu.pl/shiny/isvs/ ) for assessment of detected variants' significance. As shown by simulations, ISVS efficiently identifies and correctly classifies pathogenic mutations except for cases where the gene of interest has extremely high number of low frequency nonpathogenic variants. By applying ISVS, we found 4 known and 9 novel (p.C73Y, p.S124L, p.C194Mfs*17, c.782 + 2 T > A, c.953-5 A > G, p.L325Q, p.D334Mfs*24, p.R436G, p.M448T) TMPRSS3 variants among deaf patients. For 3 known and 5 novel variants the disease association was supported by ISVS Simulator odds >90:1. Pathogenicity of 6 novel mutations has been supported by in-silico predictions of variants' deleteriousness. By directly comparing variant prevalence in patients and controls, disease association was demonstrated only for two variants and it was relatively weak (P < 0.05). Summarizing, ISVS strategy and ISVS Simulator are useful for detection of genetic variants causing AR diseases.

Indexed as

MutationSoftwareChromosome DisordersCohort StudiesFemaleGene ExpressionGenes, RecessiveGenetic TestingHearing Loss, SensorineuralHigh-Throughput Nucleotide SequencingHumansMaleMembrane ProteinsNeoplasm ProteinsPolandSequence Analysis, DNAMembrane ProteinsNeoplasm ProteinsSerine EndopeptidasesTMPRSS3 protein, human

Identifiers

PMID28566687
PMCPMC5451398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.